Approval marks the product’s first jawline indication worldwide, with launch expected in the first half of 2027.


Mexico has approved Galderma’s Restylane Shaype for temporary chin augmentation and improvement of jawline definition, making it the first market worldwide to clear the hyaluronic acid filler for both areas. The company anticipates a launch in the first half of 2027.

The decision is the product’s first approval anywhere for the jawline. Restylane Shaype is already approved for the chin in markets including Europe, Brazil, Canada, and Thailand.

Galderma describes Restylane Shaype as the first and only “shaper” on the hyaluronic acid market. The company says the product uses the firmest hyaluronic acid gel available among market leaders in the facial filler category, with the highest G’ (a measure of firmness) in the Restylane range. It is powered by the company’s proprietary NASHA HD technology and designed to mimic bone, providing structural enhancement without surgery.

“This approval further strengthens the Restylane portfolio and reflects Galderma’s commitment to advancing science-based treatments that address evolving patient needs and growing demand for facial balancing and harmonization,” says Baldo Scassellati Sforzolini, MD, PhD, global head of research and development at Galderma, in a release.

Clinical Data

In a pivotal 12-month study of chin treatment, 83% of participants showed improved structure and definition at 3 months, and 66% at 12 months. Eighty-four percent of patients said they would agree to be treated again, and up to 97% would recommend the treatment to a friend.

For the jawline, data showed Restylane Shaype was superior to no treatment for restoring and enhancing definition, with improvements maintained for up to 2 years. Seventy percent of patients reported improved overall satisfaction with their appearance, and 82% noted natural-looking results. A further jawline study found more than 92% of patients would recommend the treatment to a friend, and more than 90% would choose it again.

Galderma cited internal market research finding that the chin is the third most treated area among existing hyaluronic acid injectable users. The company also noted that medication-driven weight loss may accentuate lower face changes by affecting facial fat distribution.

“Having new innovations in injectable treatments that allow us to address these concerns with precision while maintaining natural-looking results is incredibly valuable,” says Dr Osvaldo Vázquez, CEO of Skin Group and head of the dermatology department at Hospital Universitario Dr José Eleuterio González in Mexico, in a release.

Technique and Delivery

Galderma developed the Shayping Technique to support consistent, individualized use. It combines the company’s Assessment, Anatomy, Range, and Treatment methodology with the Facial Assessment Scale, allowing clinicians to evaluate facial balance and identify each patient’s priorities and treatment goals.

The filler is administered with a new, next-generation syringe with an ergonomic design and an optimized syringe-needle connection, intended to improve precision and control.

Galderma says the Restylane range is built on a minimally modified hyaluronic acid gel that can be readily reversed. The company also says Restylane has 30 years of innovation behind it and more than 77 million treatments administered worldwide.

ID 344709737 © Anatolii Rabizo | Dreamstime.com